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Abstract
Retinitis pigmentosa (RP) is a heterogeneous group of inherited neurodegenerative diseases affecting photoreceptors and
causing blindness. Many human cases are caused by mutations in the rhodopsin gene. An important question regarding RP
pathology is whether different genetic defects trigger the same or different cell death mechanisms. To answer this question,
we analysed photoreceptor degeneration in P23H and S334ter transgenic rats carrying rhodopsin mutations that affect
protein folding and sorting respectively. We found strong activation of calpain and poly(ADP-ribose) polymerase (PARP) in
both mutants, concomitant with calpastatin down-regulation, increased oxidative DNA damage and accumulation of PAR
polymers. These parameters were strictly correlated with the temporal progression of photoreceptor degeneration,
mirroring earlier findings in the phosphodiesterase-6 mutant rd1 mouse, and suggesting execution of non-apoptotic cell
death mechanisms. Interestingly, activation of caspases-3 and -9 and cytochrome c leakage—key events in apoptotic cell
death—were observed only in the S334ter mutant, which also showed increased expression of PARP-1. The identification of
the same metabolic markers triggered by different mutations in two different species suggests the existence of common
cell death mechanisms, which is a major consideration for any mutation independent treatment.
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Introduction
Retinitis Pigmentosa (RP) is a genetically and clinically
heterogeneous group of neurodegenerative diseases. Symptoms
of RP include night blindness, gradual loss of peripheral visual
field and eventual loss of central vision, caused by initial death of
rods and by secondary degeneration of cones, respectively [1]. The
disease prevalence is about 1/4000 [2] with autosomal dominant
(ADRP; 30–40%), autosomal recessive (56–60%) or X-linked (5–
15%) inheritance patterns [3]. To date, over 45 genes have been
identified to be responsible for RP (RetNet; http://sph.uth.tmc.
edu/Ret-Net/).
Of particular importance are RP-causing mutations in the
rhodopsin molecule. Rhodopsin is unique in the sense that it has
distinct regions that are specialized for light capturing, initiation of
the phototransduction cascade, rapid deactivation after light
absorption, as well as proper folding and sorting within the
photoreceptor membranes [4]. More than 100 different mutations
have been documented in the rhodopsin gene, accounting for 30–
40% of ADRP cases and highly variable disease phenotypes
depending on the location of the mutation [5]. The high
prevalence and heterogeneity of rhodopsin mutations make it
interesting to study the corresponding neurodegenerative mech-
anisms, not the least for the development of therapies.
The substitution of histidine for proline in the 23
rd amino acid
(P23H) at the rhodopsin N-terminus has been observed in
approximately 12% of ADRP patients [6] and is responsible for
the majority of rhodopsin-related RP cases. These patients show a
relatively mild clinical progression [7]. On the other hand, C-
terminal mutations generally have a more severe clinical
phenotype than those in other parts of the molecule [5]; possibly
because this domain is important (i) for rhodopsin sorting to rod
outer segments and (ii) for rhodopsin phosphorylation and binding
of arrestin, two steps essential for deactivation of the protein after
light absorption [8]. Hence, a mutation that interferes with both
sorting and shutoff of rhodopsin will profoundly change photore-
ceptor physiology with bearings on cell death [9].
The human mutations are faithfully reproduced in animal
models such as the P23H or the S334ter rat. Both models express
the respective mutant rhodopsins and, similar to what is seen in
human patients, the degeneration in the N-terminal P23H mutant
progresses more slowly than in the C-terminal S334ter mutant
[10]. In P23H rats rhodopsin appears to be misfolded in the
endoplasmic reticulum (ER) [11], which in turn may cause ER
stress and unfolded protein response leading to photoreceptor
death [12]. In S334ter rats the opsin is truncated at its C-terminus
and lacks the last 15 amino acid residues. Similar to the analogous
human Q334ter, this RP mutation displays fast degeneration [13].
Furthermore, the rhodopsin transgenic models exhibit protein
folding defects and intracellular aggregates, characteristics also
present in many neurodegenerative diseases including Alzheimer
and Parkinson [14].
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eventually meet the common fate of cell death, which is likely to
involve the action of common core regulators. However, despite
the availability of various animal models, the metabolic pathways
underlying the eventual loss of photoreceptors remain largely
unknown. Early studies on RP proposed apoptosis as the final
common pathway in retinal degeneration (RD) [15], although at
that point the idea that apoptosis is just one in a spectrum of cell
death principles, and as such hallmarked by caspase activation,
was not that clear. Moreover, the previous findings may have been
complicated by the fact that in rodent models mutation induced
photoreceptor death is often superseded by early postnatal
developmental cell death [16]. Indeed, recent evidence collected
in the phosphodiesterase-6 (PDE6) mutant rd1 mouse model for
RP suggests the activity of alternative, caspase-independent (and
hence non-apoptotic) routes to photoreceptor cell death [17,18]. It
appears obvious that greater knowledge about these neurodegen-
erative mechanisms is crucial for developing rational therapies.
We studied processes associated with retinal neurodegeneration
in the P23H and S334ter rats, with the aim of establishing the
metabolic pathways causing photoreceptor cell death in these RP
animal models. Intriguingly, a number of caspase-independent
processes associated with RD in the rd1 mouse [16] were also
identified in the rhodopsin mutants, suggesting that neurodegen-
erative pathways triggered by mutations in different genes are very
similar across species.
In addition, one of the mutants simultaneously displayed clear
signs of conventional, caspase-dependent apoptosis. Our findings
are therefore compatible with the idea that alternative cell death
mechanisms are, on their own, capable of govern neuronal death
in RP. Nevertheless, there are also situations when regular
apoptotic pathways are recruited as well. The findings may
facilitate future development of mutation-independent neuropro-
tective therapies in a significant group of ADRP patients.
Results
General Morphology – TUNEL staining
Analysis of P23H and S334ter retinal cross-sections during the
first postnatal (PN) month showed a progressive reduction in outer
nuclear layer (ONL) thickness compared to CD rats as described
previously [10,13]. This was matched by a decrease in the number
of photoreceptor rows, which at PN30 showed a ,40% reduction
in P23H mutants (6 ONL cell rows remaining) and 90% in
S334ter rats (,1 row), where remaining ONL cells at PN30 were
almost exclusively cones (data not shown).
We used the TUNEL assay to identify photoreceptors undergo-
ing cell death. Throughout the first PN month, P23H retina
demonstrated high levels of TUNEL-positive cells when compared
to CD, showing a peak of cell death at PN15 (P23H: 2.7%60.8 SD,
n=3; CD: 0.02%60.01 SD, n=3, P,0.001) (Fig. 1A). In S334ter
animals, a significant elevation of photoreceptor cell death was
evident already at PN10, while the highest percentage of TUNEL-
positive ONL cells was found at PN12 (S334ter: 6.1%61.1 SD,
n=3; CD: 0.02%60.01 SD, n=3, P,0.001) (Fig. 1B). At PN15,
the number of dying ONL cells – while still significantly higher than
CD – was declining because by then most photoreceptors had
disappeared (S334ter PN15: 2.2%60.8 SD, n=3, P,0.001).
TUNEL-positive cells remained detectable as late as PN30 in both
mutants. In CD controls, TUNEL-positive ONLcells weredetected
only very sporadically (Fig. 1 and Fig. 2A–B; Supporting Table S1).
For a detailed further analysis of other metabolic markers, we
chose the ages showing the peak of cell death, i.e. PN15 for P23H
and PN12 for S334ter mutants, respectively.
Activation of caspase-3, caspase-9 and cytochrome c
leakage
To study the cell death mechanisms potentially involved in
photoreceptor degeneration, we first performed an immunostain-
ing for activated caspase-3, a marker generally used to detect
apoptotic cells. Only very few positive cells were found in the ONL
of either P23H (0.1%60.04 SD, n=3) or wild-type (wt) retinas at
PN15 (CD: 0.03%60.02 SD, n=4, P.0.05) (Fig. 2C). On the
other hand, as previously described [13], activated caspase-3
immunoreactivity was significantly increased in S334ter ONL
(S334ter PN12: 5.1%60.1 SD, n=3) compared to wt control or
P23H (CD PN12: 0.01%60.00 SD, n=3,P,0.001; P23H PN12:
0.12%60.06 SD, n=3,P.0.05) (Fig. 2D; Supporting Table S1).
In line with an involvement of apoptosis in the S334ter model
only, immunostaining for two other apoptotic markers, caspase-9
cleaved at Asp353 and cytochrome c, also labelled a relatively
large number of photoreceptors in S334ter retina, but failed to do
so in wt control and P23H rats. (Supporting Fig S3).
Expression and activity of calpains
Activation of ubiquitously expressed calpain-type proteases has
been shown to be involved in neurodegeneration, including in the
Figure 1. Quantification of photoreceptor cell death during the first postnatal month. (A) Increased numbers of TUNEL stained, dying
cells in P23H rats, showing a peak of cell death at PN15. (B) In S334ter, TUNEL-positive cells were significantly elevated from PN10 onwards, increased
in number until PN12 and decreased subsequently. In both models, dying cells were detectable as late as PN30. Values are mean 6 SD from at least
three different animals; *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0022181.g001
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mechanisms [21]. Their involvement in rat rhodopsin mutants has
not been described, though. To study a potential participation of
calpains in rat RD, we first analysed expression of the major
isoforms, calpains-1 to -3. As previously described [22], calpains-1
and -2 were evenly distributed throughout all retinal layers.
Neither immunostaining nor WB analysis showed marked
differences between P23H or S334ter mutants and their
corresponding wt controls (Fig. S1).
Calpain-3 immunostaining was also present in the entire retina,
with a more intense labelling observed in a subpopulation of inner
nuclear layer and ganglion cell layer cells and in the inner
plexiform layer (IPL) in both wt and mutant rats (Fig. 2E–F).
Colocalization with choline-acetyl-transferase (ChAT) established
more prominent calpain-3 expression in amacrine and horizontal
cells and two strata of dendrites in the IPL (Fig. S2). Interestingly,
in rhodopsin mutants, ONL calpain-3 immunolabelling was more
obvious, with PN12 S334ter retina showing the strongest labelling
(Fig. 2F). This staining showed the outline of photoreceptor cells,
reflecting a membranous distribution of calpain-3. Nevertheless,
WB for calpain-3 failed to detect a significant up-regulation in
mutants (data not shown).
Figure 2. Differential regulation of cell death markers in (1) wt and (2) rhodopsin transgenic rats. (A–B) TUNEL assay for dying cells, (C–
D) caspase-3 immunostaining, (E–F) calpain 3 immunostaining, (G–H) in situ calpain activity assay, (I–J) avidin binding and (K–L) in situ PARP activity
assay. Left panels (A, C, E, G and I) correspond to PN15 animals and right panels (B, D, F, H and J) to PN12. All stainings showed large numbers of
positive cells in P23H and especially in S334ter ONL, but not in wt retina. Scale bar=50 mm.
doi:10.1371/journal.pone.0022181.g002
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increased expression [19], we additionally used an in situ assay to
study calpain activity directly. In both mutant retinas, numerous
photoreceptors were brightly labelled, whereas in wt very few
positive cells were detected (Fig. 2G–H). In P23H rats, the number
of calpain activity-positive cells was significantly elevated at PN15
(2.3%60.4 SD, n=4; CD: 0.04%60.02 SD, n=3, P,0.001)
(Fig. 3A). Calpain activity in S334ter animals increased progres-
sively reaching a peak value at PN12 (5.2%60.8 SD, n=4; CD:
0.1%60.02 SD, n=3,P,0.001) (Fig. 3B). The results thus suggest
that calpain activation is an integral component in the photore-
ceptor degeneration mechanism in both the P23H and S334ter
rats.
Calpastatin expression
As the activity of calpain is regulated by its endogenous inhibitor
calpastatin [23], we investigated its retinal expression. Calpastatin
has a predicted molecular weight of ,77 kDa but WB is known to
produce several bands with apparent molecular weights ranging
from 17 to 110 kDa and may show considerable variation between
different tissues and species [24,25]. WB identified four major
bands corresponding to 52, 60, 65, and 76 kDa (Fig. 4A).
Figure 3. Progression of metabolic cell death markers during 1st postnatal month. Percentage of labelled ONL cells in (A) P23H and (B)
S334ter transgenic rats. While in both RP animal models, most markers analysed peaked together with cell death as evidenced by the TUNEL assay,
activation of caspase-3 was absent in P23H retina but present in S334ter retina. In both mutants, calpain activity showed a delayed regression after
the peak of cell death. Values are mean 6 SD from at least three different animals. All mean 6 SD and P values are consigned in the table S1.
doi:10.1371/journal.pone.0022181.g003
Calpain and PARP Activity in Rhodopsin Mutants
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22181Quantification of the main, 52 kDa calpastatin band as well as the
expected 76 kDa band and comparison with CD retina showed a
statistically significant decrease for both bands in P23H retina
(76 kDa: P,0.05, 52 kDa: P,0.01, n=3) (Fig. 4B), and for the
52 kDa band in S334ter retina (76 kDa: P.0.05, 52 kDa:
P,0.05, n=3) (Fig. 4C).
Calpastatin immunostaining was then performed to test whether
the observed decrease in expression at the tissue level was localized
to photoreceptors. As described in other species [19], in wt,
calpastatin antibody gave a weak labelling of cellular and synaptic
retinal layers, with a stronger labelling of photoreceptor inner
segments. In both transgenic rats, calpastatin staining was reduced
in inner segments, confirming WB results (Fig. 4D–E). A reduction
of calpastatin in the mutant photoreceptors may therefore have
contributed to the calpain activation in these cells.
Oxidative DNA damage
Oxidative stress has repeatedly been implicated with photore-
ceptor degeneration [26] and hence we examined cellular
oxidative DNA damage by staining with fluorescently conjugated
avidin. Many avidin-positive cells were observed in the ONL of
both rhodopsin mutants, with PN12 S334ter retina showing the
highest levels of oxidative stress (P23H PN15: 0.9%60.2 SD,
n=3, P,0.001; S334ter PN12: 3.2%60.8 SD, n=3, P,0.001)
(Fig. 3). In wt, avidin-positive cells were observed only very
sporadically (CD PN15: 0.01%60.01 SD, n=3; PN12:
0.001%60.002 SD, n=3) (Fig. 2I–J).
PARP and PAR
An excessive activation of PARP has been found to play a major
role in many neurodegenerative diseases [27] and may contribute
to caspase-independent photoreceptor death [28]. To investigate
PARP activity in transgenic rats, we used two different
approaches. First, PARP activity was examined using an in situ
enzyme assay that detects incorporation of biotin labelled NAD
+
[29]. Only very few labelled cells were detected in CD ONL, while
in P23H (0.8%60.3 SD, n=5; CD: 0.01%60.003 SD, n=3,
P,0.001) and especially in S334ter rats (1.6%60.5 SD, n=3; CD:
0.004%60.004 SD, n=3, P,0.001), many photoreceptor nuclei
were labelled (Fig. 2K–L and Fig. 3).
Second, we performed PAR immunostaining to test for an
accumulation of poly(ADP-ribosyl)ated proteins to indirectly
confirm PARP activity. In line with the activity assay results,
numerous PAR-positive cells were observed in transgenic rat ONL
(Fig. 5A–B), with S334ter retina again showing the highest
numbers of positive cells (P23H PN15: 1.2%60.6 SD, n=3,
P,0.01; S334ter PN12: 2.9%61.2 SD, n=3, P,0.001). Only
very few PAR-positive cells were detected in CD retina (CD PN15:
0.0%60.0 SD, n=3; CD PN12: 0.01%60.01 SD, n=3) (Fig. 3).
The activity measurements as well as the stainings for its product
thus indicated PARP involvement in the degeneration in both
mutants.
PAR WB on retinal samples from wt, P23H and S334ter rats
showed a strong labelling corresponding to molecular weights
ranging from 100–240 kDa. Interestingly, in wt retina, the poly-
ADP-ribosylation of high molecular weight proteins appeared to
be decreasing with post-natal age. WB also recognized an
approximately 116 kDa band which was absent in PARP-1
knock-out mouse samples, suggesting that this band likely
indicated auto poly(ADP-ribosyl)ation of PARP-1 [30] (Fig. 5C).
Figure 4. Expression of calpastatin in rhodopsin transgenic
rats. (A) Immunoblotting for calpastatin showed decreased levels in
both, P23H and S334ter rats. (B–C) Quantification of the main
calpastatin bands at 76 and 52 kDa showed decrease expression in
both mutant retinas. This decrease in expression was statistically
significant for both bands in (B) P23H retina and (C) for the 52 kDa
band in S334ter retina. Values are mean 6 SD from three different
experiments each containing retinas from 6 animals. (D–E) Calpastatin
staining was less intense in inner segments in both rhodopsin
transgenic rats. *P,0.05; **P,0.01. Scale bar=50 mm.
doi:10.1371/journal.pone.0022181.g004
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identifying the characteristic 116 kDa band which was absent in
PARP-1 knock-out negative control (Fig. 5C). Quantification
showed a statistically significant increase of PARP-1 in S334ter but
not in P23H when compared to CD (P23H: P.0.05, n=5;
S334ter: P,0.0001, n=4) (Fig. 5D).
Differential co-localization and temporal correlation of
TUNEL with other metabolic markers
To determine the percentage of dying cells labelled for the
different biochemical markers, we performed double labelling with
TUNEL assay as an indicator for the final stages of cell death. In
both mutants, calpain and PARP activity co-localized to a large
extent with TUNEL staining (,30–40%), while avidin labelling
for oxidative DNA damage co-localized only in 12–13% of ONL
cells (Fig. 6A–C; E–G). Interestingly, caspase-3 co-localization was
observed in almost 47% of TUNEL-positive cells in S334ter
animals while in P23H retina it, in addition to being very sparse,
occurred only in 4% of TUNEL-positive cells (Fig. 6D, H). These
results suggest that photoreceptor cell death in both mutants was
highly dependent on calpain and PARP activity, with an
additional involvement of caspase activity in S334ter but not in
P23H retina.
This interpretation is corroborated by a comprehensive analysis
of progression over time for the different metabolic markers and
TUNEL assay. All studied markers were firmly correlated with the
degenerative process, with the exception of caspase-3 activity
which was unremarkable in P23H retina (Fig. 3). The complete
data sets and respective P values are presented in Supporting
Table S1.
Discussion
The neurodegenerative mechanisms governing photoreceptor
cell death have remained elusive to date. While a number of early
publications suggested an involvement of apoptosis, the present
study exposed the fact that markers for conventional apoptotic cell
death (i.e. activated caspase-3, caspase-9, cytochrome c leakage)
played a role only under specific circumstances and highlighted a
significant presence of metabolic markers for non-apoptotic cell
death in both rhodopsin mutants. Furthermore, our results
suggested that down-stream cell death mechanisms triggered by
different genetic mutations, in different species, share a number of
key components. These findings will have important implications
for the development of mutation-independent RP therapies.
Caspase activity
Photoreceptor cell death in RD has repeatedly been referred to
as apoptosis [15]. The TUNEL method is often used as apoptotic
marker even though this assay also detects non-apoptotic DNA
fragmentation, e.g. in necrosis [31]. Classical apoptosis depends on
activity of caspase-type proteases, with caspase-3 as the prototypic
mediator and executioner of apoptotic cell death [32]. Previous
studies found caspase-3 activation in the S334ter model [13]. We
confirmed these results, however with two important consider-
ations: (i) in S334ter retina, caspase-3 and caspase-9 activity along
with cytochrome c leakage appear concomitantly with calpain and
PARP activity, indicating that these mechanisms are executed side
by side; (ii) in P23H rat, caspase-3 activity was not significantly
higher than in age-matched wt suggesting that P23H caspase-3
activity relates to developmental but not to mutation induced cell
death. This intriguing discrepancy between the two RP models
demonstrates how changes in the location of rhodopsin mutations
may determine the phenotype leading to caspase-independent cell
death in one case or to degeneration that involves caspase
activation in the other.
The activity of caspase-3 independent pathways in both rat
mutants and in rd1 mice [19,20] may explain why previous
experimental approaches using caspase inhibition afforded no or
only partial photoreceptor protection [13,33].
Figure 5. PAR accumulation and PARP-1 expression in
rhodopsin transgenic rats. (A–B) Accumulation of PAR was found
in many cells in P23H and especially in S334ter retinas. (C) PAR WB
identified a band at ,116 kDa which most likely represented PARP-1
itself and additionally strong labelling of proteins ranging from 100 to
240 kDa, suggesting poly(ADP-ribosyl)ation. Retinal PAR levels were
increased in both transgenic animals. (C–D) PARP-1 protein expression
was similar in wt and P23H retina, but significantly increased in S334ter.
PARP-1 knock-out retina was used as negative control. Values are mean
6 SD from four different experiments each containing retinas from 6
animals. ***P,0.001. Scale bar=50 mm.
doi:10.1371/journal.pone.0022181.g005
Calpain and PARP Activity in Rhodopsin Mutants
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22181Figure 6. Fluorescence micrographs demonstrating the double-labelling of TUNEL with other metabolic markers. (A2–H2) Double
labelling of TUNEL with: (A1, E1) calpain assay, (B1, F1) PARP assay, (C1, G1) avidin and (D1, H1) caspase-3 in (A–D) P23H retina at PN15 and (E–H)
S334ter retina at PN12 transgenic rats. (A3–H3) Merged pictures. (A4–H4) Right panel indicates the percentages of co-labelled cells in the ONL. In
both mutants calpain and PARP activity co-localized with TUNEL in ,30–40% of cells, while avidin-binding co-localized in 12–13% with TUNEL.
Caspase-3 co-localization was observed in almost 47% of TUNEL-positive cells in S334ter but only in 4% in P23H retinas. Scale bar=25 mm.
doi:10.1371/journal.pone.0022181.g006
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Ca
2+-dependent calpain-type proteases play important roles in
many neurodegenerative diseases [34]. In rhodopsin transgenic
rats, we did not find obvious expression changes at the tissue level,
although the increased visualization of calpain-3 in immunofluo-
rescence may refer to changes in expression, localization, and/or
activation within photoreceptors.
Importantly, however, we found strongly elevated calpain
activity in rhodopsin transgenic rats matching with a significant
decrease in the expression of the endogenous inhibitor calpastatin,
which to a large extent regulates the calpains [35,36]. Our results
in rhodopsin mutant retina are in line with earlier studies on rd1
retina where calpastatin down-regulation corresponds to a strong
up-regulation of calpain activity [19] and strengthen the view that
calpain activation is an important step in retinal neurodegener-
ation [16,19,20]. Therefore, in the context of neuroprotective
treatments, targeting calpain activity may address a larger
spectrum of RP-causing mutations and might thus be more
effective than inhibiting caspase activity, evident only in the
S334ter mutant.
DNA damage and PARP activity
Oxidative stress has repeatedly been identified as an important
contributor to inherited RD [37]. However, at present it is still
unclear whether oxidative stress is causally involved in primary RD
(i.e. rod degeneration) or whether it is a secondary phenomenon
causing mutation-independent death of cones and inner retina
neurons [16]. Reactive oxygen species generated for instance by
excessive mitochondrial metabolism [38] will create characteristic
oxidized compounds, such as 8-oxo-guanosine, the main oxidation
product in the DNA [39]. The accumulation of 8-oxo-guanosine
observed in photoreceptor nuclei of P23H and S334ter rat retina
corresponds to previous findings in rd1 retina [29,40]. In both
mutant rats and mice oxidative DNA damage may be crucial to
trigger activation ofPARP, a ubiquitously expressed nuclearprotein,
which is activated by DNA damage and seen as an important
mediator of DNA repair [41]. Nevertheless, an excessive activation
of PARP and the production of high levels of neurotoxic PAR
polymer [21,42], have also been connected with cell death, in
particular inthe context of neurodegenerative diseases, where PARP
has been proposed to play a central role in a novel form of caspase-
independent cell death, tentatively termed PARthanatos [27].
We found clear evidence for PARP over-activation in
degenerating P23H and S334ter photoreceptors, concomitant
with an accumulation of PAR, very similar to what was previously
observed in the rd1 mouse [29]. While in P23H rats and rd1 mice,
strong increases in PARP activity were not matched by increased
expression, in S334ter retina an up-regulation of both PARP
activity and PARP-1 expression was detected. The reasons for this
PARP up-regulation exclusively in S334ter retina remain unclear,
but may be related to the more severe form of degeneration in this
model. However, it does not seem to be a compensatory
upregulation due to cleavage by the activated caspase-3, since
we saw no signs of increased PARP cleavage product in S334ter
tissue. Our data clearly indicates PARP activation as a key step in
photoreceptor degeneration regardless of the causal mutation and
proposes PARP as a target for neuroprotective treatments.
Temporal progression of metabolic cell death markers
Both rhodopsin transgenic models are characterized by an early
death of photoreceptors, and thus, mutation induced cell death
overlapped temporally with developmental cell death [43]. Still,
the metabolic markers studied here were strongly increased only in
RD mutants, indicating that developmental processes had only a
minor, if any, influence. The P23H retina showed a comparatively
slower progression of photoreceptor cell death than S334ter, in
line with earlier studies [10,13]. In S334ter rat, caspase-3
activation was elevated, however, it coincided numerically and
temporally with calpain activation during the second PN week,
indicating that these two proteolytic systems are activated and
executed in parallel. This co-activation suggests some form of
cross-talk between caspases and calpains [44] and may explain at
least partially, the extremely fast progression of degeneration in
this model. Alternatively, it would also be possible that a different
cell death mechanism was triggered because of the faster
progression of S334ter degeneration (possibly linked to a stronger
genetic insult). However, in the rd1 mouse, which displays
essentially the same rate of cell death, only non-apoptotic markers
are observed [15], suggesting that the cell death pathway was not
per se determined by the speed of degeneration.
In P23H retina, caspase-3 activity clearly plays only a minor, if
any, role while at the same time calpain activity is very prominent.
The implications for a therapy of RP in this model are important
since these results suggest that targeting exclusively the caspase
cascade – as was previously proposed for the rd1 mouse [33] - is
unlikely to give positive results while, on the other hand, targeting
non-apoptotic events such as calpain or PARP activation may
have beneficial effects [20,28]. A detailed identification of all
associated and interacting proteins involved in photoreceptor cell
death is fundamental, because if a single enzyme is blocked, the
cell may still be able to activate/continue other mechanisms or
routes to die [44,45].
Finally, the increase of all analysed markers (i.e. caspase-3
activation, calpain and PARP activity, PAR accumulation,
oxidative DNA damage, TUNEL) coincided and followed a
similar pattern. The metabolic markers correlated temporally and
even co-localized with TUNEL staining, proposing that these
events occurred relatively late in the degenerative process.
Alternatively, this close correlation may also be explained when
assuming that cell death, once triggered, is executed very rapidly.
Remarkably, in both transgenic models, after the peak of
degeneration, the number of cells showing calpain activity
exceeded the number of TUNEL-positive cells. This could be
due to a higher detection sensitivity of the calpain assay, but may
also indicate that proteolytic activity of calpains persists at times
when the nuclear DNA has already disintegrated.
In conclusion, we here provide for the first time a comprehen-
sive overview of several important metabolic markers associated
with photoreceptor cell death in two mutant rhodopsin models for
RP. Furthermore, we highlight differences and similarities
between the two models, as well as between different rodent
species. While in S334ter retina, cell death was associated with
both apoptotic and non-apoptotic markers, P23H mutation
induced cell death appeared to be restricted to non-apoptotic
mechanisms. Interestingly, in both mutants, cell death was clearly
connected to activation of calpain and PARP, as well as
accumulation of PAR and oxidatively damaged DNA, similar to
what has previously been observed in rd1 mouse retina. Taken
together, these findings suggest that non-apoptotic cell death plays
an important role in inherited photoreceptor degenerations, in
general, while apoptosis may additionally occur in certain
mutations such as rhodopsin C-terminal truncations.
This in turn may have important implications for future therapy
development because (i) it expands the perimeter from apoptotic to
other, alternative mechanisms which in turn may yield a number
of novel targets for neuroprotective treatments (ii) the same non-
apoptotic processes were observed in the two rhodopsin mutants as
well as in the PDE6 mutant rd1 mouse and hence strongly improve
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All procedures were approved by the Tuebingen University
committee on animal protection and performed in compliance
with the ARVO statement for the use of animals in Ophthalmic
and Visual Research. Protocols compliant with 1 4 paragraph 3 of
the German law on animal protection were reviewed and
approved by the ‘‘Einrichtung fu ¨r Tierschutz, Tiera ¨rztlichen
Dienst und Labortierkunde’’ (Anzeige/Mitteilung nach 1 4 vom
28.04.08 and 29.04.10). All efforts were made to minimize the
number of animals used and their suffering.
Animals
Homozygous P23H and S334ter rhodopsin transgenic rats
(produced by Chrysalis DNX Transgenic Sciences, Princeton, NJ)
of the line Tg(P23H)1Lav and Tg(S334ter)3Lav (P23H-1 and
S334ter-3) were kindly provided by Dr. M. M. LaVail (University
of California, San Francisco, CA) and bred in our animal housing
facility. We employed heterozygous P23H and S334ter rats,
obtained by crossing with wt, CD rats (CDH IGS Rat; Charles
River, Germany) to reflect the genetic background of ADRP. CD
animals were used as wild type (wt) controls.
Histology
Rats were euthanized at different ages (PN8–PN30). Fixed (4%
paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) for
30 min at 4uC and unfixed eyecups were embedded in cryomatrix
(Tissue-Tek, Leica, Bensheim, Germany). Radial 12 mm sections
were stored at 220uC.
TUNEL Assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay was performed using an in situ cell death detection
kit (Fluorescein or TMR; Roche Diagnostics GmbH, Mannheim,
Germany). For co-localization with calpain or poly(ADP-ribose)
polymerase activity, the activity-stained sections were fixed in 4%
PFA and the TUNEL staining was performed afterwards. For co-
localization with cleaved caspase-3 or avidin, staining was followed
by TUNEL staining.
Immunohistochemistry
Sections were incubated overnight at 4uC with primary antibodies
(Table 1). Immunostaining was performed employing the avidin-
biotin-peroxidase technique (Vectastain ABC system, Vector labora-
tories, Burlingame, CA). Fluorescence immunocytochemistry was
performed using Alexa FluorH 488 conjugated secondary antibody
(Molecular Probes, Inc. Eugene, USA). Negative controls were
carried out by omitting the primary antibody.
Calpain activity Assay
Calpain activity was investigated with an enzymatic in situ assay
[19]. Briefly, unfixed cryosections were incubated for 15 min in
calpain reaction buffer (CRB; 25 mM HEPES, 65 mM KCl,
2 mM MgCl2, 1,5 mM CaCl2, 2 mM DTT) and then sections
were incubated at 35uC for 1 h in the dark in 2 mM fluorescent
calpain substrate 7-amino-4-chloromethylcoumarin, t-BOC-L-
leucyl- L-methionine amide (CMAC, t-BOC-Leu-Met; Molecular
Probes, Inc. Eugene, USA). Fluorescence was generated by
calpain-dependent cleavage of t-Boc-Leu-Met-CMAC.
Histology for oxidative DNA damage: Avidin Staining
Avidin staining can be used to identify oxidatively damaged
DNA, since it labels 8-OHdG (8-oxoguanine) [40,46]. Retinal
sections were incubated at room temperature for 1 h with Alexa
FluorH 488 conjugated avidin (1:80). Negative controls were treated
with avidin staining solution pre-adsorbed with 12 nM 8-Hydroxy-
29-deoxyguanosine (Calbiochem, Merck KGaA, Darmstadt, Ger-
many) and 50 nM biotin (Vector laboratories, Burlingame, CA).
Poly(ADP-ribose) polymerase (PARP) enzyme activity
assay
Unfixed cryosections were incubated in a avidin/biotin blocking
kit (Vector Laboratories, Burlingame, USA), followed by incubation
at 37uC for 2 h in PARP reaction mixture containing 10 mM
MgCl2, 1 mM DTT, 5 mM biotinylated NAD
+ (Trevigen, Gai-
thersburg, USA) in 100 mM Tris buffer with 0.2% Triton X-100
(pH 8.0). Incorporated biotin was detected by avidin, Alexa FluorH
488 conjugate (1:800, 1 h at room temperature). For controls
biotinylated NAD
+ was omitted from the reaction mixture [29].
Western Blot (WB)
Retinas were homogenized in buffer (20 mM Tris-HCl
(pH 7.4), 0.25 M sucrose, 1 mM EDTA, 0.5 g/L BSA, and
Table 1. List of antibodies used in this study.
Antigen Source/Cat. Number Dilution
IF/IHC WB
Calpastatin Novus Biologicals/NB120-5582 1:50 1:5000
Cleaved Caspase-3 (Asp175) (5A1E) Cell Signalling/9664 1:300 -
Cleaved Caspase-9 (Asp353) Abcam/ab52298 1:100 -
Calpain LP85 and LP82 (Capn3) Millipore Chemicon/AB81011 1:50 1:5000
m-Calpain, large (catalytic) subunit (Capn2) Millipore Chemicon/AB81023 1:100 1:1000
m-Calpain large subunit, clone P-6 (Capn1) Millipore Chemicon/MAB3082 1:100 1:1000
Choline Acetyltransferase (ChAT; clone 1E6) Chemicon/MAB 305 1:300 -
Cytochrome C (clone 7H8.2C12) BD Pharmingen/556433 1:2000 -
Poly (ADP-Ribose) Polymerase (PARP; clone C2-10) BD Pharmingen/556362 - 1:1000
PAR (10H) Enzo/ALX-804-220 1:200 1:1000
doi:10.1371/journal.pone.0022181.t001
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with protease inhibitors (Set III; Calbiochem, Schwalbach,
Germany). Samples were mixed with Laemmli SDS-PAGE sample
buffer, boiled for 5 min, separated on 10% SDS-polyacrylamide
gels, and electrotransferred to PVDF membranes (Bio-Rad,
Mu ¨nchen, Germany). Membranes were blocked with blocking
solution (RotiH-Block, Carl Roth, Karlsruhe, Germany) and
incubated overnight at 4uC with primary antibody (see table 1)
diluted in TBS-T buffer (150 mM NaCl, 13 mM Tris-HCl
[pH 7.5], 0.02% Triton-X-100) or PBS-T (0.1% Tween in case
of PARP-1 and PAR) with 5% dry milk. The reaction was
visualized with horseradish peroxidase–conjugated secondary
antibody and chemiluminescence reagent (ECL Plus; Amersham).
Quantification of relative WB band intensities was done following
a tutorial written by Luke Miller (http://lukemiller.org/index.
php/2010/11/analyzing-gels-and-western-blots-with-image-j/).
Microscopy, cell counting, and statistical analysis
Light and fluorescence microscopy was performed on an Axio
Imager Z1 ApoTome Microscope, equipped with a Zeiss Axiocam
digital camera. Images were captured using Zeiss Axiovision 4.7
software; representative pictures were taken from central areas of
the retina. Adobe Photoshop CS3 (Adobe Systems Incorporated,
San Jose, CA) was used for primary image processing.
For cell quantifications, pictures were captured of whole radial
slices using Mosaix mode of Axiovision 4.7 at 206magnification.
Labelled cells were counted manually. The total number of cells
was determined by dividing outer nuclear layer (ONL) area
through average cell size. The number of positive cells was then
divided by the total number of ONL cells giving the percentage of
positive cells. All data given represent the means and standard
deviations from three sections each, for at least three different
animals. Statistical comparisons between experimental groups
were made using one-way ANOVA and Bonferroni’s correction
using Prism 5 for Windows (GraphPad Software, La Jolla, CA).
Supporting Information
Figure S1 Calpain 1 and 2 immunolabelling in rhodop-
sin transgenic rats. Antibodies directed against (A–B) calpain 1
and (C–D) calpain 2 are evenly distributed throughout all retinal
layers. Immunostaining did not show differences between (A2, C2)
P23H at PN15 or (B2, D2) S334ter at PN12 mutants and (A1,
B1, C1 and D1) their corresponding wt controls. Scale bar
100 mm.
(TIF)
Figure S2 Calpain 3 immunolabelling in rhodopsin
transgenic rats. Double staining with an antibody directed
against Choline-acetyl-transferase (ChAT) shows that calpain-3 is
expressed in cholinergic amacrine cells, horizontal cells and the
two strata of dendrites in the IPL. Scale bar 25 mm.
(TIF)
Figure S3 Caspase-9 cleaved ASP353 and cytochrome c
immunolabelling in rhodopsin transgenic rats. Both
stainings showed large numbers of positive cells in S334ter
ONL, but not in wt or P23H retina. Scale bar=50 mm.
(TIF)
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